32828-81-2
Chemical Structure
Picotamide
- CAS No.: 32828-81-2
- Formula:C21H20N4O3
- Molecular Weight:376.41
IUPAC Name: 4-methoxy-N1,N3-bis(pyridin-3-ylmethyl)isophthalamide
InChIKey: KYWCWBXGRWWINE-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(OC)C(C(NCC2=CC=CN=C2)=O)=C1)NCC3=CC=CN=C3
Biological Activity: Picotamide is an orally active TXA2 receptor and TXA2 synthase inhibitor. Picotamide inhibits ADP (HY-W010918)-, Arachidonic acid (HY-109590)-, and Collagen (HY-NP003)-induced platelet aggregation, reduces TXA2 production during coagulation, and does not inhibit PGI2 synthesis in endothelial cells. Picotamide inhibits contractions induced by α1-adrenergic receptor agonism, TXA2 mediation, and neurogenic (electrical field stimulation-induced) factors in human prostatic smooth muscle, and broadly inhibits agonist-induced contractions of porcine interlobar renal and coronary arteries. Picotamide can be used in research related to thromboembolic diseases, atherosclerosis, and lower urinary tract symptoms[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Picotamide | 99.76% | Picotamide is an orally active TXA2 receptor and TXA2 synthase inhibitor. Picotamide inhibits ADP (HY-W010918)-, Arachidonic acid (HY-109590)-, and Collagen (HY-NP003)-induced platelet aggregation, reduces TXA2 production during coagulation, and does not inhibit PGI2 synthesis in endothelial cells. Picotamide inhibits contractions induced by α1-adrenergic receptor agonism, TXA2 mediation, and neurogenic (electrical field stimulation-induced) factors in human prostatic smooth muscle, and broadly inhibits agonist-induced contractions of porcine interlobar renal and coronary arteries. Picotamide can be used in research related to thromboembolic diseases, atherosclerosis, and lower urinary tract symptoms. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liu X, et al. Design, synthesis, and biological evaluation of 4-methoxy-3-arylamido-N-(substitutedphenyl)benzamide derivatives as potential antiplatelet agents. Archiv der Pharmazie. 2020 Feb;353(2):e1900231.
- [2]. Buccellati C, et al. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1, 3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations[J]. The Journal of pharmacology and experimental therapeutics, 2006, 317(2): 830-837.
- [3]. Hennenberg M, et al. The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction. Journal of biomedical science. 2013 Jul 02;20(1):46.
- [4]. Liu XJ, et al. Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents. Bioorganic & medicinal chemistry. 2021 Sep 15;46:116390.
- [5]. Li B, et al. Picotamide inhibits a wide spectrum of agonist-induced smooth muscle contractions in porcine renal interlobar and coronary arteries. Pharmacology research & perspectives. 2021 May;9(3):e00771.
